PL2152261T3 - Leczenie zmian wywołanych przez wirusy - Google Patents

Leczenie zmian wywołanych przez wirusy

Info

Publication number
PL2152261T3
PL2152261T3 PL08733422T PL08733422T PL2152261T3 PL 2152261 T3 PL2152261 T3 PL 2152261T3 PL 08733422 T PL08733422 T PL 08733422T PL 08733422 T PL08733422 T PL 08733422T PL 2152261 T3 PL2152261 T3 PL 2152261T3
Authority
PL
Poland
Prior art keywords
treatment
virally induced
induced lesions
lesions
virally
Prior art date
Application number
PL08733422T
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Andreas Suhrbier
James Harrison Aylward
Original Assignee
Leo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39925109&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2152261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007902266A external-priority patent/AU2007902266A0/en
Application filed by Leo Laboratories Ltd filed Critical Leo Laboratories Ltd
Publication of PL2152261T3 publication Critical patent/PL2152261T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08733422T 2007-04-30 2008-04-30 Leczenie zmian wywołanych przez wirusy PL2152261T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007902266A AU2007902266A0 (en) 2007-04-30 Treatment of virally induced lesions
PCT/AU2008/000596 WO2008131491A1 (en) 2007-04-30 2008-04-30 Treatment of virally induced lesions
EP08733422.3A EP2152261B1 (en) 2007-04-30 2008-04-30 Treatment of virally induced lesions

Publications (1)

Publication Number Publication Date
PL2152261T3 true PL2152261T3 (pl) 2016-06-30

Family

ID=39925109

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08733422T PL2152261T3 (pl) 2007-04-30 2008-04-30 Leczenie zmian wywołanych przez wirusy

Country Status (23)

Country Link
US (1) US9895334B2 (pl)
EP (1) EP2152261B1 (pl)
JP (1) JP5497629B2 (pl)
KR (1) KR101485883B1 (pl)
CN (1) CN101742996B (pl)
AU (1) AU2008243705B2 (pl)
BR (1) BRPI0810806A2 (pl)
CA (1) CA2685473C (pl)
CY (1) CY1119269T1 (pl)
DK (1) DK2152261T3 (pl)
ES (1) ES2564173T3 (pl)
HK (1) HK1134450A1 (pl)
HR (1) HRP20160181T1 (pl)
HU (1) HUE028713T2 (pl)
IL (1) IL201796A (pl)
MX (1) MX2009011865A (pl)
MY (1) MY154484A (pl)
NZ (1) NZ580702A (pl)
PL (1) PL2152261T3 (pl)
RU (1) RU2506951C2 (pl)
SI (1) SI2152261T1 (pl)
UA (1) UA98328C2 (pl)
WO (1) WO2008131491A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
EP1838330A4 (en) 2004-12-13 2010-07-07 Peplin Research Pty Ltd TREATMENT OF SOLID TUMORS
UA98328C2 (uk) 2007-04-30 2012-05-10 Пеплин Рисерч Пти Лтд Лікування шкірних ушкоджень, індукованих вірусом
PT2395993T (pt) 2009-02-13 2017-07-18 Leo Laboratories Ltd Tratamento cutâneo
RS56337B1 (sr) 2010-04-16 2017-12-29 Leo Pharma As Ortorombični kristalni ingenol mebutat
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
EP2655312A1 (en) 2010-12-22 2013-10-30 Leo Laboratories Limited 3-acyl-ingenols ii
AU2011348637B2 (en) 2010-12-22 2015-08-20 Leo Laboratories Limited Ingenol-3-acylates III and ingenol-3-carbamates
US9388124B2 (en) 2010-12-22 2016-07-12 Leo Laboratories Limited Ingenol-3-acylates I
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101406201B1 (ko) 2011-10-19 2014-06-12 한국생명공학연구원 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
CN104136081B (zh) * 2012-03-02 2018-05-15 阿马佐尼亚菲托药品有限公司 再活化潜伏hiv病毒的巨大戟二萜醇衍生物
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
RU2015102095A (ru) * 2012-06-26 2016-08-10 Лео Лэборетериз Лимитед 3-о-гетероарилингенол
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
EP2931246A1 (en) * 2012-12-12 2015-10-21 Leo Laboratories Limited Gel compositions
WO2014198807A1 (en) * 2013-06-12 2014-12-18 Leo Laboratories Limited A topical composition
KR101520428B1 (ko) * 2013-11-22 2015-05-14 충남대학교산학협력단 대극 추출물을 유효성분으로 포함하는 항인플루엔자용 조성물
CN104188979B (zh) * 2014-08-11 2017-01-11 泰州祥泰康华医药科技有限公司 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物在制备治疗缺血性脑损伤药物中的应用
CN104523705A (zh) * 2014-12-10 2015-04-22 南京大学 闭花木酮的o-(咪唑基)乙基衍生物在制备抗病毒药物中的应用
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
JP7495679B2 (ja) * 2019-10-03 2024-06-05 国立大学法人京都大学 ヒトパピローマウイルス性疣贅に対する貼付剤
EP3915549A1 (en) * 2020-05-26 2021-12-01 Merck Patent GmbH Senescence inducers for use in the treatment and/or prevention of virus induced diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
RU2174396C2 (ru) * 1997-03-20 2001-10-10 Панацея Биотек Лтд. Фармацевтическая композиция для подавления и лечения аноректальных и ободочно-кишечных болезней
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
EP1838330A4 (en) 2004-12-13 2010-07-07 Peplin Research Pty Ltd TREATMENT OF SOLID TUMORS
JP2009516651A (ja) * 2005-11-14 2009-04-23 ペプリン リサーチ プロプライエタリー リミティッド 癌を治療するための他の薬剤と組み合わせたアンゲロイル置換インゲナンの使用
GB0525680D0 (en) * 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
UA98328C2 (uk) 2007-04-30 2012-05-10 Пеплин Рисерч Пти Лтд Лікування шкірних ушкоджень, індукованих вірусом

Also Published As

Publication number Publication date
NZ580702A (en) 2012-03-30
UA98328C2 (uk) 2012-05-10
IL201796A0 (en) 2010-06-16
RU2009144100A (ru) 2011-06-10
EP2152261A1 (en) 2010-02-17
IL201796A (en) 2016-11-30
HUE028713T2 (en) 2016-12-28
MY154484A (en) 2015-06-30
CY1119269T1 (el) 2018-02-14
CA2685473C (en) 2015-09-01
KR20100017464A (ko) 2010-02-16
MX2009011865A (es) 2009-12-04
CN101742996B (zh) 2013-08-21
WO2008131491A1 (en) 2008-11-06
CA2685473A1 (en) 2008-11-06
JP5497629B2 (ja) 2014-05-21
US20100204318A1 (en) 2010-08-12
RU2506951C2 (ru) 2014-02-20
JP2010524978A (ja) 2010-07-22
AU2008243705A1 (en) 2008-11-06
SI2152261T1 (sl) 2016-05-31
EP2152261A4 (en) 2013-01-02
DK2152261T3 (en) 2016-03-07
HK1134450A1 (zh) 2010-04-30
AU2008243705B2 (en) 2013-10-10
BRPI0810806A2 (pt) 2014-10-29
KR101485883B1 (ko) 2015-01-27
HRP20160181T1 (hr) 2016-05-06
US9895334B2 (en) 2018-02-20
EP2152261B1 (en) 2015-12-09
CN101742996A (zh) 2010-06-16
ES2564173T3 (es) 2016-03-18

Similar Documents

Publication Publication Date Title
HK1134450A1 (zh) 治療病毒引起的損害
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
HK1154575A1 (zh) 用於治療增生性疾病的不對稱吡咯並苯並二氮雜卓二聚物
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
ZA200906126B (en) Use of IL-23 antigonists for treatment of infection
EP2251064A4 (en) HYGIENE MASK FOR THE PROTECTION OF OTHERS
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
ZA200806808B (en) Treatment of stressed patients
HK1170908A1 (en) Novel compounds and therapeutic use thereof for protein kinase inhibition
IL208236A0 (en) Use of cathepsin c
ZA201000225B (en) Treatment of depression
EP2184353A4 (en) TREATMENT OF INFLUENZA
GB0708452D0 (en) Treatment of nuclear studge
GB0723100D0 (en) Treatment of HFnEF
EP2164494A4 (en) Methods of Treatment
AU2007902266A0 (en) Treatment of virally induced lesions
GB0717139D0 (en) Treatment of hepatitis C
GB0819543D0 (en) Treatment of proteostatic disease
GB0817859D0 (en) Treatment of proteostatic disease
GB0816217D0 (en) Treatment of hepatitis C
HU0800656D0 (en) Effective use of tea-composition
GB0809319D0 (en) The treatment of puritus
GB0625602D0 (en) Treatment of sialorrhoea